Payment overview · 2025
General Payments
$59.25
2 reported records · 2 companies
Healthcare provider profile · identity verified
Farhan Rehman, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · NEW PORT RICHEY, FL · NPI 1750722708
Verified facts
What the public records show
CMS Open Payments records show Farhan Rehman, M.D. received $59.25 in general payments during 2025 across 2 reported records.
Cipher Pharmaceuticals US LLC accounted for 68.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Synthroid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $40.59 | 68.5% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.66 | 31.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.25 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $40.59 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $40.59 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $18.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
38 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 563 | 217 |
| Levothyroxine Sodium | Levothyroxine Sodium | 292 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 115 |
| Gabapentin | Gabapentin | 256 | 93 |
| Lisinopril | Lisinopril | 250 | 96 |
| Losartan Potassium | Losartan Potassium | 217 | 88 |
| Omeprazole | Omeprazole | 213 | 84 |
| Furosemide | Furosemide | 188 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 185 | 71 |
| Ozempic | Semaglutide | 184 | 40 |
| Metformin Hcl | Metformin Hcl | 170 | 62 |
| Pantoprazole Sodium | Pantoprazole Sodium | 168 | 68 |
| Metoprolol Succinate | Metoprolol Succinate | 167 | 68 |
| Trazodone Hcl | Trazodone Hcl | 167 | 62 |
| Potassium Chloride | Potassium Chloride | 148 | 42 |
| Carvedilol | Carvedilol | 133 | 47 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 43 |
| Famotidine | Famotidine | 120 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 112 | 48 |
| Tramadol Hcl | Tramadol Hcl | 112 | 28 |
| Fluticasone Propionate | Fluticasone Propionate | 109 | 45 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 46 |
| Montelukast Sodium | Montelukast Sodium | 107 | 31 |
| Tamsulosin Hcl | Tamsulosin Hcl | 107 | 45 |
| Ibuprofen | Ibuprofen | 103 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 103 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 36 |
| Meloxicam | Meloxicam | 93 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 91 | 28 |
| Buspirone Hcl | Buspirone Hcl | 85 | 28 |
| Sertraline Hcl | Sertraline Hcl | 84 | 32 |
| Quetiapine Fumarate | Quetiapine Fumarate | 79 | 17 |
| Eliquis | Apixaban | 78 | 29 |
| Mounjaro | Tirzepatide | 74 | 18 |
| Allopurinol | Allopurinol | 73 | 23 |
| Simvastatin | Simvastatin | 73 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 72 | 28 |
| Jardiance | Empagliflozin | 71 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 69 | 17 |
| Celecoxib | Celecoxib | 68 | 21 |
| Glipizide Er | Glipizide | 68 | 22 |
| Alprazolam | Alprazolam | 67 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 15 |
| Prednisone | Prednisone | 61 | 31 |
| Fluoxetine Hcl | Fluoxetine Hcl | 59 | 22 |
| Metformin Hcl Er | Metformin Hcl | 55 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 55 | 19 |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 24 |
| Pregabalin | Pregabalin | 53 | 16 |
| Atenolol | Atenolol | 52 | 21 |
| Xarelto | Rivaroxaban | 52 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 51 | 16 |
| Azithromycin | Azithromycin | 50 | 35 |
| Methylprednisolone | Methylprednisolone | 50 | 43 |
| Bupropion Xl | Bupropion Hcl | 43 | 17 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 43 | 35 |
| Ezetimibe | Ezetimibe | 42 | 17 |
| Ondansetron Odt | Ondansetron | 42 | 18 |
| Spironolactone | Spironolactone | 42 | 16 |
| Alendronate Sodium | Alendronate Sodium | 41 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 41 | 25 |
| Dicyclomine Hcl | Dicyclomine Hcl | 41 | 18 |
| Finasteride | Finasteride | 41 | 14 |
| Baclofen | Baclofen | 40 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 40 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | 14 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 39 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 39 | 12 |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 38 | 13 |
| Synthroid | Levothyroxine Sodium | 38 | 15 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 37 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 28 |
| Glimepiride | Glimepiride | 36 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 13 |
| Methocarbamol | Methocarbamol | 36 | 13 |
| Naproxen | Naproxen | 36 | suppressed |
| Glipizide | Glipizide | 35 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | 11 |
| Diazepam | Diazepam | 33 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 32 | 19 |
| Memantine Hcl | Memantine Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 31 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Paroxetine Hcl | Paroxetine Hcl | 30 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 29 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 17 |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Lorazepam | Lorazepam | 26 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 25 | 21 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Bumetanide | Bumetanide | 24 | 11 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 24 | suppressed |
| Lactulose | Lactulose | 24 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 20 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 19 | suppressed |
| Lamotrigine | Lamotrigine | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 13 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | suppressed |
| Temazepam | Temazepam | 18 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 17 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 16 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 16 | suppressed |
| Acyclovir | Acyclovir | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Nystatin | Nystatin | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Zonisamide | Zonisamide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.25 · 2 records | Cipher Pharmaceuticals US LLC | CREON, Natroba, Spinosad | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error